Eisai ups commitment to oncology with new US R&D subsidiary
This article was originally published in Scrip
Eisai is to pump at least $200 million over 10 years into exploratory research at a new US subsidiary set up to strengthen its activities in oncology R&D.
You may also be interested in...
Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.